LOGIN  |  REGISTER
Assertio
Chimerix

Phreesia Named to The Software Report’s “Top 100 Software Companies” for the Third Consecutive Year

November 22, 2024 | Last Trade: US$25.16 1.32 5.54

ALL-REMOTE COMPANY/WILMINGTON, Del. / Nov 22, 2024 / Business Wire / Phreesia, a leader in patient intake, outreach and activation, has been selected by The Software Report as one of the “Top 100 Software Companies of 2024.” The annual program evaluates companies based on a range of criteria, including product functionality, customer satisfaction, corporate reputation, innovative capabilities, organizational depth, ESG involvement and long-term viability. This is the third consecutive year Phreesia has been named to the list.

“We are proud once again to be recognized as a leader in SaaS innovation,” said Phreesia CEO Chaim Indig. “This honor reflects Phreesia’s dedication to investing in products that help drive better health outcomes. We remain committed to making care easier every day and transforming the healthcare experience for both patients and providers.”

In the announcement, The Software Report describes its list of honored companies as those that “are making a major impact on the software industry” in 2024. Phreesia is ranked 11 out of the 100 companies, up four spots from 2023. Other awardees this year include Hootsuite, Celigo and Enable.

For more information on Phreesia, visit www.phreesia.com.

About Phreesia

Phreesia is the trusted leader in patient activation, giving providers, life sciences companies and other organizations tools to help patients take a more active role in their care. Founded in 2005, Phreesia enabled approximately 150 million patient visits in 2023—more than 1 in 10 visits across the U.S.—scale that we believe allows us to make meaningful impact. Offering patient-driven digital solutions for intake, outreach, education and more, Phreesia enhances the patient experience, drives efficiency and improves healthcare outcomes. To learn more, visit phreesia.com.

Chimerix

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB